Grants and Contracts Details
GOALS AND OBJECTIVES (SCIENTIFIC AIMS) 1.1 Primary Aims To determine whether the efficacy of treatment with selumetinib as measured by event-free survival (EFS) is non-inferior to treatment with carboplatin/vincristine (CV) in previously untreated Neurofibromatosis type 1 (NF1)-associated low-grade glioma (LGG). To determine whether visual acuity (VA) using Teller Acuity Cards (TAC), in patients with NF1-associated LGG within the optic pathway, is better in those treated with selumetinib compared to CV.
|Effective start/end date||3/1/21 → 12/9/21|
- Childrens Hospital of Philadelphia: $2.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.